| 摘要 |
The invention provides and describes solid state 17alpha-ethynyl-5alpha-androstane-3alpha,17beta-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17alpha-ethynyl-5alpha-androstane-3alpha,17beta-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17alpha-ethynyl-5alpha-androstane-3alpha,17beta-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17alpha-ethynyl-5alpha-androstane-3alpha,17beta-diol and uses of such formulations in treating the described conditions. |
